Itepekimab
-
Itepekimab Meets Primary Endpoint in COPD Phase 3 Trial
Regeneron and Sanofi announced mixed results from their Phase 3 AERIFY trials of itepekimab for COPD. AERIFY-1 met its primary endpoint by reducing moderate or severe exacerbations in former smokers, while AERIFY-2 failed. The trials evaluated itepekimab’s impact on exacerbation frequency. Safety profiles appeared consistent across both trials. The companies are reviewing the full data.
